Decitabine and Cedazuridine

Phase 2Small molecule

Taiho Oncology, Inc.

Decitabine and Cedazuridine is one of 274 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

273

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

ChondrosarcomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Chronic Myelomonocytic LeukemiaActive, not recruiting

Myelodysplastic SyndromeRecruiting

Prostate CancerActive, not recruiting

Acute Myeloid LeukemiaRecruiting

Myelodysplastic SyndromesActive, not recruiting

Acute Myeloid Leukemia Post Cytotoxic TherapyRecruiting

Anatomic Stage III Breast Cancer AJCC V8Suspended

LymphomaPhase 1

Active, not recruiting

ChondrosarcomaPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 1

Active, not recruiting

Chronic Myelomonocytic LeukemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Recruiting

Prostate CancerPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Recruiting

Myelodysplastic SyndromesPhase 1

Active, not recruiting

Acute Myeloid Leukemia Post Cytotoxic TherapyPhase 1

Recruiting

Anatomic Stage III Breast Cancer AJCC V8Phase 1

Suspended

Showing 10 of 11 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Decitabine and Cedazuridine

Taiho Oncology, Inc.

Phase 2

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Chronic Myelomonocytic Leukemia

NCT04655755

Phase 2Active, not recruiting

Chronic Myelomonocytic Leukemia

NCT05600894

Q4 2026

Phase 2Recruiting

Myeloid Leukemia

NCT05007873

Phase 2Active, not recruiting

Acute Myeloid Leukemia

NCT04746235

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT04817241

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT04657081

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia12 trials

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT06802523·53 enrolled

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Active, not recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1/2·NCT04657081·101 enrolled

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04746235·85 enrolled

Show 9 more trials

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04817241·5 enrolled

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04975919·20 enrolled

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06672146·93 enrolled

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT05396859·13 enrolled

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07437950·126 enrolled

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05010772·125 enrolled

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07153497·132 enrolled

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04774393·84 enrolled

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Myelodysplastic Syndromes2 trials

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Active, not recruiting· Otsuka logo

Otsuka·Phase 1/2·NCT06091267·72 enrolled

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06484062·54 enrolled

Myelodysplastic Syndrome2 trials

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT05010122·42 enrolled

A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06577441·54 enrolled

Chronic Myelomonocytic Leukemia2 trials

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05600894·132 enrolled

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04655755·52 enrolled

Myeloproliferative Neoplasms1 trial

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06661915·62 enrolled

8 more indications

Lymphoma1 trial

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05272384·32 enrolled

Prostate Cancer1 trial

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT05037500·8 enrolled

Myeloid Leukemia1 trial

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05007873·70 enrolled

Adult Subject1 trial

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

Withdrawn·RRace Oncology Ltd·Phase 1·NCT05456269

Blast Phase Myeloproliferative Neoplasm1 trial

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Recruiting·UUniversity of Washington·Phase 2·NCT07148947·27 enrolled

Chondrosarcoma1 trial

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04340843·19 enrolled

Acute Myeloid Leukemia Post Cytotoxic Therapy1 trial

A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07012044·47 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

Suspended·NNational Cancer Institute (NCI)·Phase 1·NCT05673200·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Decitabine and Cedazuridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Decitabine and Cedazuridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Decitabine and Cedazuridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Taiho Oncology, Inc.

Decitabine and Cedazuridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Acute Myeloid Leukemia12 trials

Myelodysplastic Syndromes2 trials

Myelodysplastic Syndrome2 trials

Chronic Myelomonocytic Leukemia2 trials

Myeloproliferative Neoplasms1 trial

Lymphoma1 trial

Prostate Cancer1 trial

Myeloid Leukemia1 trial

Adult Subject1 trial

Blast Phase Myeloproliferative Neoplasm1 trial

Chondrosarcoma1 trial

Acute Myeloid Leukemia Post Cytotoxic Therapy1 trial

Anatomic Stage III Breast Cancer AJCC v81 trial

References

Drug Info

Quick Facts

Related News